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Abstract
Background: The adhesion of Plasmodium falciparum parasitized red blood cell (PRBC) to human endothelial cells
(EC) induces inflammatory processes, coagulation cascades, oxidative stress and apoptosis. These pathological
processes are suspected to be responsible for the blood-brain-barrier and other organs’ endothelial dysfunctions
observed in fatal cases of malaria. Atorvastatin, a drug that belongs to the lowering cholesterol molecule family of
statins, has been shown to ameliorate endothelial functions and is widely used in patients with cardiovascular
disorders.
Methods: The effect of this compound on PRBC induced endothelial impairments was assessed using endothelial
co-culture models.
Results: Atorvastatin pre-treatment of EC was found to reduce the expression of adhesion molecules and
P. falciparum cytoadherence, to protect cells against PRBC-induced apoptosis and to enhance endothelial
monolayer integrity during co-incubation with parasites.
Conclusions: These results might suggest a potential interest use of atorvastatin as a protective treatment to
interfere with the pathophysiological cascades leading to severe malaria.
Background
Malaria remains a major threat to public health with
40% of the world population currently at risk. Every
year, an estimated 500 million cases of clinical malaria
and at least one million deaths are reported [1,2]. Fatal
cases of malaria occur mainly in young children in
Africa and consist of an acute neurological syndrome
(cerebral malaria), either in isolation or concomitantly
with multi-organ failure (pulmonary distress, acute renal
failure) [3]. Anti-malarial drugs, such as quinine and
artemisinin derivatives are administered intravenously as
an emergency treatment. However, although these drugs
effectively and rapidly clear parasites from the blood,
15%-20% of patients still die, probably as the result of
impaired host responses [4,5]. Such a situation together
with the difficulty in developing vaccines highlights the
urgent need of novel strategies for complement
therapeutics.
The severity of Plasmodium falciparum infection
depends largely on the ability of parasitized red blood
cells (PRBC) to adhere on endothelial cells (EC) and
sequester in the capillary network of vital organs (e.g.
brain, lungs, kidneys, liver.) Moreover, activation of
endothelial cells resulting from the adhesion of infected
erythrocytes leads to an overexpression of different
mediators, such as adhesion molecules ("hyperadhesion”
phenomenon), pro-inflammatory cytokines, coagulation
factors and contributes by itself to the pathology [6].
Among endothelial receptors, some are known to inter-
act with PRBC, mainly via PfEMP1 (P. falciparum ery-
throcyte membrane protein 1), a highly polymorphic
parasite ligand exported on the infected erythrocyte sur-
face. A number of the cytoadherence receptors have
been identified, such as ICAM-1, CD36, VCAM-1 or P-
selectin [7]. It was previously shown that P. falciparum
adhesion to human endothelial cells can specifically trig-
ger proinflammatory gene expression [8-10], oxidative
stress [11] and caspases activation [11], further leading
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[12,13]. In addition PRBC adhesion to EC induces redox
and rho-kinase dependent EC activation and apoptosis,
which can be reversed respectively by the addition of
anti-oxidants or fasudil rho-kinase inhibitor [12,14].
Atorvastatin is an oral drug that lowers the level of cho-
lesterol in the blood. All statins, including atorvastatin,
prevent the production of cholesterol by blocking the
enzyme HMGCoA reductase. However, there is increasing
evidence that statins may also exert effects beyond choles-
terol lowering. Many of these cholesterol-independent or
“pleiotropic” vascular effects of statins appear to involve
restoring or improving the endothelial function through
increasing the bioavailability of nitric oxide, promoting re-
endothelialization, reducing oxidative stress, and inhibiting
inflammatory responses [15]. Thus, the endothelium-
dependent effects of statins are thought to contribute to
many of the beneficial effects of statin therapy in cardio-
vascular disease [16]. In addition to its lipids lowering
effects, atorvastatin has been shown to promote nitric
oxide (NO) production by decreasing caveolin-1 expres-
sion in EC, regardless of the level of extracellular
LDL-cholesterol [17]. Statins retard the initiation of ather-
osclerosis formation through the improvement of NO
bioavailability by both up-regulation of endothelial-nitric
oxide synthase (eNOS) mRNA and decrease of superoxide
anion O2
- production in EC [18]. Statins modulate the
adhesion cascade at multiple points by targeting both the
endothelium and leukocytes and affect cell adhesion by
inhibiting chemokine expression (MCP-1) in activated leu-
kocytes and endothelial cells. There is also evidence that
statins decrease ICAM-1 expression in stimulated EC and
monocytes [19]. The effects of atorvastatin on mature EC
are correlated with the activation of the anti-apoptotic Akt
pathway, as determined by the phosphorylation of Akt and
eNOS [20]. Therefore, activation of Akt represents a
mechanism that can account for some of the beneficial
side effects of statins.
Given the pleiotropic effects on endothelium of statins
in general and atorvastatin in particular, atorvastatin
was hypothesized to be useful as a protective drug
against P. falciparum induced endothelial damages. Pri-
mary human lung endothelial cells (HLEC) were used
here in co-culture with P. falciparum-infected erythro-
cytes Previous studies have already shown that PRBC
adhesion triggers inflammation, oxidative stress and
apoptosis within lung endothelial cells [9,11,12,21,22].
Moreover, acute respiratory distress as a complication of
malaria infection is rare, but with a vey high rate of
m o r t a l i t y[ 3 , 2 3 ] .T h ed a t ap resented in this manuscript
show that, concomitantly with increased expression
of Akt within HLEC, atorvastatin reduces adhesion
of P. falciparum-infected erythrocytes, and as a
consequence, prevents the endothelial damages induced
by PRBC.
Methods
Culture of human endothelial cell
Primary endothelial cells were isolated from human lung
(HLEC) after enzymatic digestion and selected using a
continuous gradient and immunomagnetic purification
technique, as described elsewhere [24]. Endothelial cells
of ninth to twelfth passages derived from one batch
were used for the experiments. Before use, cells were
verified for their expression of ICAM-1, CD36, Von
Willebrand factor, VCAM-1, CD31, E/P-selectin and
CSA. HLEC were raised in M199 medium (Gibco), sup-
plemented with 10 μg/ml of endothelial cell growth sup-
plement (Upstate, NY) and 10% of fetal calf serum
(Biowest), at 37°C with 5% CO2,u s i n g8c h a m b e r -
Labtek (Nunc International, Napervil), 35 mm glass bot-
tom dishes (MatTek corp.), 96-well plates (Costar), or
Transwell insert supports (Corning LifeSciences).
Plasmodium falciparum culture
The P. falciparum 3D7 clone was used for these experi-
ments. Infected erythrocytes were maintained in culture
according to Trager and Jensen’s technique in a suspen-
sion of erythrocytes in RPMI (Gibco) supplemented
with 8.3 g/l of Hepes, 2.1 g/l of NaHCO, 0.1 mg.ml
-1 of
gentamycin, 2 g/l of dextrose, and 0.4% of Albumax II
(Gibco, Invitrogen Corporation) [25]. The 3D7 clone
was characterized for adhesion phenotype as previously
described [25] and adheres to ICAM-1 and CD36. For
each experiment, parasite cultures were enriched in
mature forms by Plasmagel floating [26]. Briefly, ery-
throcytes were harvested from 5 to 10% parasitized cul-
tures and centrifuged 5 minutes at 2000 rpm. Cells were
resuspended in Plasmion
® and incubated for 20 minutes
at 37°C. The upper fraction containing mature tropho-
zoites and schizonts was collected and washed three
times in RPM, before adequate adjustment of the hema-
tocrit and parasitemia.
Real time RT-PCR
HLECs were treated with atorvastatin (Pfizer) for
24 hours, and total RNA was prepared using RNeasy
mini kit (Qiagen). RT and quantitative PCR were per-
formed as previously described [27]. Primers used were
as follow: ICAM-1: forward 5’-GCAATGTGCAA-
GAAGA TAGCCA-3’ reverse 5’-GGGCAAGACCT-
CAGGTC ATGT-3’ VCAM-1: forward 5’-GAGTACG
CAAACA CTTTATGTCAATGT-3’,r e v e r s e5 ’-CTCG
TC CTTTCGGGACCG-3’, P-selectin forward 5’-AGA
CTCCC CACCAATGTGTGA-3’, reverse 5’-CCAC-
GAGTGTCA GAACAATCCA-3’ CD36 forward 5’-TA
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CATAGATG GACCTGCAA-3’ HPRT1 forward 5’-AA
AGGACCC CACGAAGTGTT-3’ reverse 5’-TCAAGG
GCATATCCTACAACAA-3’.
Plasmodium falciparum adhesion assay
HLEC were raised in Labtek until confluence. Suspen-
sions of mature pRBC were deposited onto cells and
incubated for one hour at 37°C with gentle shaking
every 10 minutes. After the incubation, the unbound
pRBC were removed and the preparation was fixed for
30 minutes at room temperature with 2% glutaralde-
hyde, before staining with Giemsa. The number of para-
sites adhering to 700 HLEC was counted by direct
observation with light microscope.
Nucleosome release assay
The proportion of apoptotic cells was assessed by mea-
suring the intracytoplasmic release of mono- and oligo-
nucleosomes as, using Cell Death Dtection ELISA
®
(Roche) previously described [11]. Briefly, HLEC were
raised in 96-well plate (Costar) until confluence and
exposed 24 hours to PRBC (hematocrit 5% parasitemia
50%) or RBC (hematocrit 5%). After 5 PBS washing
steps, endothelial cells were lysed and cytoplasms were
analysed for their nucleosomes content.
Endothelial barrier integrity assay
Confluent endothelial monolayer were obtained by seed-
ing 30,000 HLEC on Transwell permeable support
(polyester, 3 μm pores, 6.5 mm diameter) and raised in
M199 medium supplemented as above during 36 hours.
Endothelial monolayers were then exposed during
12 hours to PRBC suspensions at 1% parasitemia and
0.5% of hematocrit. Transwell compartments were then
washed three times and cell monolayers on Transwell
inserts were transferred to a new plate containing PBS.
Evans Blue (0.5 mg/mL) (ICN Biomedicals) was then
added in the ‘upper compartments’. After 5 min of incu-
bation at 37°C and 5% CO2,t h e‘under compartments’
were collected for optic density analysis of diffused
Evans Blue (630 nm) with a standard microplate reader
(Bio-Tek™ EL311SX) [12].
Western blot
Cells (1 × 10
6) were lysed in Laemmli sample buffer and
protein extracts were separated by SDS-PAGE, trans-
ferred to nitrocellulose, blocked (5% non-fat dry milk) in
Tris-buffered saline (TBS: 20 mM Tris-HCl pH 7.5,
150 mM NaCl) plus 0.05% Tween-20 and incubated
with the primary antibody over night at 4°C in TBS-
0.5% non-fat dry milk. The membrane was washed and
incubated with PO-conjugated secondary antibody for
two hours at room temperature. Secondary antibodies
on western blot membranes were revealed using the
ECL system.
Immunofluorescence and confocal microscopy
HLEC were raised in 35 mm glass bottom dishes, before
fixation with 1% paraformaldehyde for 5 min, permeabi-
lized and then incubated with polyclonal anti-Akt antibody
(Cell Signaling) for 2 h in PBS 3% BSA at room tempera-
ture. FITC-secondary antibody was added and incubated
for 1 h at room temperature. After several washing steps,
samples were incubated with methanol at -20°C for
10 min, mounted with Vectashield medium and analysed
by confocal microscopy.
Statistical analysis
Differences between groups were analysed for statistical
significance using the Games-Howell post-hoc (SPSS
software). A pv a l u eat least less than 0.05 was consid-
ered significant.
Results and discussion
Atorvastatin prevents P. falciparum-induced endothelial
adhesion molecules upregulation
In addition to their anti-cholesterol function, statins are
also involved in expression regulation of some adhesion
molecules in lymphocytes, monocytes and endothelial
cells. The role of statin atorvastatin in the control of
expression of CD36, ICAM-1, VCAM-1 and P-Selectin,
four adhesion molecules that are involved in tethering,
rolling and adhesion processes, was analysed in a co-
culture of endothelial cells and P. falciparum parasitized
red blood cells (PRBC). Atorvastatin doses, ranging from
0.01 to 1 microM, showed no toxic effect on human
lung endothelial cells (HLEC) in vitro,d o s e sr a n g i n g
from 1.5 microM to 5 microM showed low toxic effects,
whereas atorvastatin doses above 6 microM showed
mitochondrial toxic effects on HLEC (MTT mitochon-
drial-based cell viability assay). HLEC were pre-treated
24 hours with 1 microM of atorvastatin before being
e x p o s e dt oP R B Co rc o n t r o lR B Cd u r i n gf o u rh o u r s .
Total RNA of EC was extracted and adhesion molecules
expression was assessed by qPCR. On the one hand, our
data show that PRBC increase the expression of
endothelial cell (EC) adhesion molecule ICAM-1 and
P-selectin. Indeed, PRBC cytoadherence was previously
shown to increase cytoadherence itself through increase
of EC adhesion molecules expression (’hyperadhesion’)
[28], contributing to the microcirculation perturbation
in severe malaria pathology. More importantly, the data
clearly showed that the P. falciparum-induced increase
of ICAM-1 and P-Selectin expression is suppressed by
atorvastatin pre-treatment (Figure 1).
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P. falciparum-induced endothelial apoptosis
Given the effect of atorvastatin endothelial treatment on
the expression of adhesion molecules, its effect on
PRBC ability to adhere on endothelial cells was analysed
(Figure 2). HLEC were pre-incubated 24 hours with var-
ious doses of atorvastatin (0.01, 0.025, 0.05, 0.1, 0.5,
1 microM), before being exposed to PRBC ad
cytoadherence assay. The data showed that PRBC
cytoadherence is significantly decreased by doses that
are higher than 0.5 microM of atorvastatin. The cytoad-
herence decreased to 44% ± 9, for EC pre-incubated
with 1 microM of atorvastatin compared to untreated
controls. Atorvastatin is thus capable of interfering effi-
ciently with the adhesion of P. falciparum infected ery-
throcytes on endothelial cells.
PRBC adhesion was previously shown to specifically
trigger endothelial apoptosis [9]. The effect of atorvasta-
tin (0.01-1 microM) on endothelial apoptosis was tested
in the co-culture model. HLEC were pre-treated
24 hours with atorvastatin before being exposed for four
hours to PRBC or control uninfected RBC. Endothelial
apoptosis was then quantitatively assessed using a
method to determine HLEC intracytoplasmic content of
nucleosomes, a well known late apoptosis marker
(Figure 3). The data showed decreasing endothelial
apoptosis correlated with increasing doses of atorvasta-
tin pre-treatment. PRBC-induced apoptosis was found
completely abolished with doses higher than 0.05
microM.
Atorvastatin protects endothelial barrier integrity from
P. falciparum-induced impairments
PRBC were previously observed to trigger specific signal-
ing pathway that leads to endothelial barrier permeabiliza-
tion [12]. Given the effects of atorvastatin pre-treatments
on endothelial apoptosis, atorvastatin was tested whether
it could have also beneficial properties on endothelial bar-
rier integrity. HLEC were pre-treated with 1 microM of
atorvastatin for 24 h and then with PRBC for 4 hours.
Figure 1 Effect of atorvastatin on endothelial expression of
adhesion molecules: HLEC were cultured alone or co-cultured with
RBC (hematocrit 5%), or PRBC for 4 h (parasitemia 50%, hematocrit
5%) after 24 hours of pretreatment or not with 1 microM of
atorvastatin (A, 1 microM). Then, cells were washed and total RNA
was isolated. qPCR was done using primers for amplification of
human ICAM-1, VCAM-1, P-selectin and CD36. As internal control,
we used HPRT. The expression is shown as fold induction compared
to control non-treated cells (n = 6), **P < 0.01; *** P < 0.005.
Figure 2 Atorvastatin decreasing effect on P. falciparum
endothelial cytoadherence: HLECs were pre-treated with various
doses of atorvastatin ((0.01, 0.025, 0.05, 0.1, 0.5, 1 microM)) for 24
hours before addition of RBCs or PRBCs at a haematocrit of 5% and
a parasitemia of 50% for 1 hour. After removal of unbound
erythrocytes, cells were stained with Giemsa and the number of
adhered pRBC to 700 HLEC was counted. Data are the mean ±SD of
pRBC cytodherence (n = 4), **P < 0.01.
Figure 3 Effect of atorvastatin on P. falciparum-induced
endothelial apoptosis: HLEC cells were pre-treated with or without
different concentrations of atorvastatin ((0.01, 0.025, 0.05, 0.1, 0.5, 1
microM)) for 24 h and then co-cultured 4 hours with PRBC
(hematocrit 5% parasitemia 50%) or RBC (hematocrit 5%).
Intracytoplasmic content of nucleosomes was assessed (n = 4), **P
< 0.01; *** P < 0.005.
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integrity was assessed by the standard Evans blue extru-
sion method. Figure 4 shows that co-culture of PRBC with
endothelial cells induces endothelial barrier permeability,
compared to unexposed control cells or RBC exposed
cells. Pre-treatment of endothelial cells with atorvastatin 1
microM could strongly decrease PRBC-inducced barrier
permeabilization. This result suggests that atorvastatin is
also very efficient to protect endothelial barrier integrity
from P. falciparum-induced impairments. However, it
should be noted that the relevance of these quantitative
data must be restricted to the detection method of stan-
dard Evans blue extrusion.
Atorvastatin increases Akt expression in endothelial cells
exposed to P. falciparum
Among the pleiotropic effects of statins, their role in the
activation of cell survival protein kinase B or Akt signaling
pathway is well established [29,30]. Given the protective
effect of atorvastatin against cell death in our endothelial-
PRBC co-culture model, the effect of atorvastatin treat-
ment on endothelial Akt expression was analysed. HLEC
were treated 24 hours with 0.05, 1 or 5 microM of atorvas-
tatin. Figure 5A shows Western blot data and its respec-
tive quantitative analysis by densitometry imaging. It
shows that pre-treatment of increasing doses of atorvasta-
tin up-regulates Akt expression in HLEC. Similarly, Akt
expression was up-regulated in co-cultures of HLEC
exposed to RBC or PRBC. The effect of atorvastatin on the
endothelial up-regulation of Akt expression was confirmed
by confocal microscopy imaging analyses (Figure 5B).
These data suggest that atorvastatin increases the Akt
expression within endothelial cells.
The data presented here demonstrate that atorvastatin
can be used to reduce the cytoadherence of P. falciparum
on endothelial cells, which is one of key events, along
with the inflammatory burst, involved in the pathogenesis
of human severe malaria cases. Atorvastatin can decrease
the expression of adhesion molecules and also prevents
the PRBC-induced overexpression of adhesion molecules.
Moreover, atorvastatin shows an ability to strongly pro-
tect endothelial cell against P. falciparum-induced collat-
eral damages, cell apoptosis and endothelial barrier
permeabilization.
The observed cytoprotection effect on endothelial cells
m a ym a i n l yb ed u et ot h ed e c r e a s eo fP R B Ca d h e s i o n
through the down-regulation of adhesion molecules, as
PRBC contact was previously shown to specifically trigger
pro-inflammatory and pro-apoptotic signaling cascades
[9]. Moreover, atorvastatin stimulates Akt expression
within HLEC, which is the major actor of anti-apoptotic
and endothelial cell survival pathways [29]. Endothelial
protection of atorvastatin appears then to be ‘pleiotropic’
via anti-adhesive, anti-inflammatory and anti-apoptotic
synergistic effects. Indeed, PRBC cytoadherence is known
to activate many deleterious cascades such as oxidative
stress, via mitochondrial ROS (radical oxygen species)
production, rho-kinase and NF-kappa B-dependent sig-
naling to induce ‘hyperadhesion’ phenomenon, endothe-
lial activation and apoptosis [8,11,12,14,28,31]. When
phosphorylated, Akt inactivates pro-apoptotic elements
such as Bad, preventing mitochondrial ROS release, and
caspase 9 [32]. Statins can also increase the bioavailability
and the physiological production of endothelial nitric
oxide (NO) via Akt phosphorylation and downstream
effector endothelial NO-synthase (eNOS), and via the
stabilization of eNOS mRNA [30,33]. NO has many cru-
cial functions in vascular endothelium particularly in
maintaining permanently anti-inflammatory and anti-
adhesive endothelium homeostasis. NO-donors have cur-
rently been under investigation in cerebral malaria
adjunctive emergency treatments, the efficiency of which
remains controversial [34]. Indeed, the deleterious
scavenging of NO by ROS has not been considered with
antioxidant co-treatment yet. As regard their molecular
‘pleiotropic’ effects, particularly with the antioxidant and
the NO bioavailability promotion, statins may then be
highly relevant to ‘shield’ the endothelium against both
PRBC induced impairments and uncontrolled host
responses in severe malaria cases.
There is increasing interest of using statins as comple-
mentary therapeutic to anti-plasmodial molecules. How-
ever, these studies with statins were performed on
infected erythrocytes only and have shown interestingly
to have a direct inhibitory effect on P. falciparum
growth in vitro, using high doses ranging from 120 to
240 microM [35], from 5 to 40 microM [36] or from
Figure 4 Protective role of atorvastatin against P. falciparum-
induced endothelial barrier impairment: HLEC were pre-treated
with 1 microM of atorvastatin for 24 h and then co-cultured with
PRBC (hematocrit 0.5%/parasitemia 1%) or RBC (hematocrit 0.5%) for
4 h. The endothelial barrier permeability was estimated by Evan
Blue diffusion through an endothelial monolayer. Results are
represented related to the OD of the control HLEC cells. A,
atorvastatin. (n = 6), *** P < 0.005, NS: non significant.
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Page 5 of 9Figure 5 Atorvastatin promotes endothelial expression of Akt: A. Western blot. HLEC were pre-treated with different concentrations of
atorvastatin (0.05, 1 or 5 microM) for 24 h and then cultured or co-cultured with PRBC (at 5% of hematocrit and 50% of parasitemia) or RBC (at
5% of hematocrit) for 4 h. Cells were harvested, washed, protein extracts separated by SDS-PAGE, transferred to nitrocellulose and
immunoblotted with anti-Akt and anti-tubulin antibodies, the latter as internal control. Molecular mass of the corresponding proteins is shown.
The Western blot data were then quantitatively analysed by densitometry imaging (ratio Akt/Tubulin). Similar results were obtained in three
independent experiments. B. Confocal microscopy. HLEC were pre-treated with different concentrations of atorvastatin (0.05, 1 or 5 microM) for
24 h and then exposed to PRBC (at 5% of hematocrit and 50% of parasitemia) or RBC (at 5% of hematocrit) for 4 h. Fixed cells were stained with
anti-Akt antibody and analysed by confocal microscopy. Similar results were obtained in 3 independent experiments. (Bar: 20 μm).
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Page 6 of 92.5 to 10.8 microM [37]. Atorvastatin was shown to be
10 times more active against P. falciparum compared to
mevastatin, simvastatin, lovastatin, fluvastatin or pravas-
tatin [36], suggesting that atorvastatin is the best candi-
date among statins for therapy prospects in malaria
treatment. Simvastatin was also used in mouse model of
cerebral malaria (C57BL/6 mice infected with Plasmo-
dium berghei), but failed to decrease significantly parasi-
temia or to prevent death [38,39]. Atorvastatin may
have a beneficial effect on mice survival, only when
administered in combination with artesunate [40].
Indeed, atorvastatin was recently shown to reduce the
IC50 of the anti-plasmodial activity of quinine, meflo-
quine and dihydroartemisinin [41-43]. However, the
pathogenesis of cerebral malaria in murine model relies
solely on the inflammatory response unlike the patho-
genesis of human cerebral malaria. Indeed, the cytoad-
herence phenomenon does not exist in P. berghei mice
infections [44,45]. Atorvastatin was used in pre-treat-
ment to specifically evaluate the potential effects
on endothelial cells. Endothelial damage is almost uni-
versal in severe malaria pathogenesis and statins have
proved their efficiency in clinical use for 20 years against
cardiovascular diseases [29]. Interestingly, significant
endothelial protection effects were obtained with doses
as low as 100 nanoM, 500 nanoM or 1 microM.
Although the ‘pleiotropic’ effects of statins are well
documented, the precise molecular mechanism by which
the PI3K/Akt/eNOS pathway is activated remains
unknown [29,46]. Since the cholesterol lowering property
of statins by itself ameliorates the endothelial function,
statins beneficial effects were for long attributed to the
inhibition of HMG-CoA reductase and the cholesterol
synthesis pathway. However, the endothelial function
improvement was shown to occur earlier than cholesterol
lowering and independently from the cholesterol rate in
blood serum [47,48]. Statins are inhibiting the synthesis
of mevalonate, the second biochemical reaction in the
cholesterol synthesis pathway. Mevalonate is also an
important precursor of isoprenoid intermediates such as
farnesyl pyrophosphate (FPP) or geranylgeranyl pyropho-
sphate (GGPP). Isoprenoids serve as cell surface inner
membrane-anchoring molecules to functionalize Rho-
GTPases, such as Rho (GGPP) and Ras (FPP) [49,50], key
signaling molecules, after geranylation and farnesylation
post-translational modifications. Rho-GTPases act as
molecular switches (active and inactive when bound to
GTP and GDP, respectively), and are the first intermedi-
ates of the intracellular signaling engagement of these
receptors with the downstream effector Rho-kinase. We
have previously demonstrated that P. falciparum-induced
endothelial collateral damages are precisely dependent on
Rho-kinase signaling [12]. Rho-kinase pathway by many
aspects is antagonist to PI3K/Akt/eNOS endothelial cell
survival pathway [46]. In fact, strong endothelial protec-
tive effects, obtained with atorvastatin against P. falci-
parum, may likely be related to both rho-kinase pathway
inhibition and Akt cell survival pathway promotion.
However, it was previously reported that the rho-kinase
inhibition by fasudil could not decrease significantly the
number of parasites and P. falciparum cytoadherence
[12,51].
Conclusions
In conclusion, data from this report demonstrate that
HMG-CoA reductase inhibitor atorvastatin prevents
P. faciparum cytoadherence and confers the ability to the
endothelium to resist against consequent cellular
damages. In conclusion, this study suggests that atorvas-
tatin may be a good candidate for further studies or clini-
cal trials on the use of statins in malaria treatment.
Moreover, the safety of statins on malaria treatment
needs to be addressed, since these molecules were not
originally designed for these therapeutic approaches.
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